Bacteriophage therapy: viruses that eliminate resistant bacteria

A bacteriophage therapy has gained prominence as a promising alternative in the fight against lethal bacterial infections. It involves the use of specific viruses (phages) that attack only bacteria, offering a safe, precise and effective treatment for cases in which traditional antibiotics fail.

Why therapy is urgent

Infections caused by antibiotic-resistant bacteria result in around 6 million deaths a year and generate an estimated cost of US$ 1 trillion to health systems. A therapy appears as a solution, for example:

• Overcoming the limitations of conventional antibiotics
• Treating resistant infections
• Reduce the economic and social impact of these diseases

What bacteriophages are and how they work

Bacteriophages (or phages) are viruses that exclusively infect bacteria. Therefore, when they attach to the bacterial cell, they insert their genetic material, multiply and cause lysis of the cell, killing the bacteria without affecting human cells or beneficial flora. .

Mechanism of action of bacteriophage therapy

Before listing its applications, see how bacteriophage therapy acts in practice:

• Phage binds to target bacteria
• Injects DNA or RNA, controlling the cell
• New phages are produced
• Bacteria are destroyed by cell lysis

In addition, this selective mechanism offers personalized treatment, preserving the patient's microbiome and minimizing side effects.

Benefits of bacteriophage therapy

The adoption of bacteriophage therapy has several advantages over traditional methods, for example:

• Specificity: only attacks pathogenic bacteria
• Efficacy against superbugs
• Reduction of bacterial resistance
• Potential for chronic infections not resolved by antibiotics

Challenges and limitations of bacteriophage therapy

Despite the promising progress, the bacteriophage therapy still faces obstacles to becoming widely accessible:

• Need to identify specific phages for each infection
• Regulation and standardization of clinical treatments
• Clinical studies still in the consolidation phase
• Possible development of resistance to the phages themselves

Recent advances and future prospects

The renewed interest in phages was expected, since new classes of antibiotics are rare. For this reason, research shows their potential in both clinical and agricultural settings, as well as the promise of use in resistant infections and bacterial biofilms.

In addition, organizations and research centers have intensified clinical trials, seeking to validate protocols, apply genetic sequencing and better understand the dynamics of these viruses